MDxHealth S.A. operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MDxHealth S.A. with three other
miscellaneous service companies in Europe:
Bioinvent International AB
of SWEDEN
(2020
sales of 147.37 million Swedish Kronor [US$17.02 million]
of which 52%
was Revenue from collaboration agreements as),
Kiadis Pharma NV
of NETHERLANDS
(17.50 million Euros [US$20.49 million]
), and
Tissue Regenix Group PLC
which is
based in UNITED KINGDOM
(£12.83 million [US$17.55 million]
of which 58%
was Orthopaedics).
Sales Analysis.
Sales were up sharply during the second
quarter of 2021 versus the previous year's second quarter.
During the second
quarter of 2021, sales at MDxHealth S.A. totalled
8.94 million Euro.
This is
an increase of 146.7%
from the 3.62 million Euro in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled 13.19 million Euro, which is
49.9% higher
than through the first two quarters of 2020.
MDxHealth S.A. reported sales of 16.09 million Euro (US$18.84 million)
for the
year ending
December of 2020.
This
represents
an
increase of 52.6%
versus 2019, when the company's sales were 10.54 million Euro.
Despite this increase, sales are still
well
below the level achieved in 2018, when MDxHealth S.A.
reported sales of 24.10 million Euro.
The sales level in 2020 was fairly close to the level five years ago: in 2015, MDxHealth S.A. had sales
of 15.99 million Euro.